11 research outputs found
Usporedba razliÄitih doza joda 131 u ablaciji ostatnog tkiva Å”titnjaÄe zbog papilarnog karcinoma, te uloga rekombinantnog humanog tireotropina (rhTSH) kod ablacije
Despite many years of experience in thyroid cancer treatment the agreement about the optimal I-131 activity needed for successful thyroid remnant ablation, has not yet been established. Some authors advocate a dosimetric approach to I-131 therapy, but most centers prefer to give standard activities which can range from as low as 1110 GBq (30 mCi) of I-131 to as high as 5550 GBq (150 mCi). During past decades the activity of 4440 (120 mCi) of I-131 used to be applied in our Department as standard ablative activity with excellent outcome. Encouraged with the results of quantitative dosimetric investigations in our patients we recently reduced the amount of administered radioiodine trying to be more rationale considering radiation burden for patients and staff as well as the cost of treatment. Therefore, we started to practice a lower activity regime by administration of 888 MBq (24 mCi) to 1850 MBq (50 mCi) of I-131. Successful application of radioiodine requires hypothyroid state (TSH level higher than 30 mIU/L) achieved either by stimulation of endogenous TSH production after withdrawal of suppressive therapy or by administration of human recombinant TSH (rhTSH).
The aim of this study was to compare ablation rates obtained with different I-131 activities in large group of patients. The first study included 466 patients divided into four groups according to I-131 activities given after total thyroidectomy for papillary thyroid cancer: 888 MBq/24 mCi (group A, n =168), 1480 MBq/40 mCi (group B, n = 125), 1850 MBq/50 mCi (group C, n = 65) and 4440 MBq/120 mCi (group D, n = 108). Second goal, in smaller selected group of patients was to evaluate the successfulness of thyroid remnant ablation after application of 1850 MBq (50 mCi) of radioiodine in hypothyroid patients as well as in euthyroid patients previously prepared with human recombinant thyrotropin. Those study included patients with intrathyroid papillary carcinoma, smaller than 1.5 cm, without any sign of metastatic disease. Patients were divided into two groups according to method of preparation for thyroid remnant ablation (hypothyroid group 42 pts, rhTSH group 35 pts), and the rate of ablation was compared. Ablation outcome was assessed by whole body scan in hypothyroid state 6-9 months after ablation and finally 18-21 months after the treatment.
The rate of successful ablation was similar in the group of patients who received 24 and 40 mCi (75% and 71.2%, respectively). The higher rate of ablation (87.69% and 90.74%) was achieved in the groups treated with 50 and 120 mCi of radioiodine. The ablation rates at the first follow-up examinations (59.5%, 67.2%, 73.9%, 80.6%) were lower than at second control study (75.0%, 71.2%, 87.7%, 90.7%) in all groups, respectively. Time required for thyroid remnant ablation appears to be ā„18 months.
There was no significant difference between rates of ablation in two groups of patients received 1850 MBq (50 mCi) of radioiodine prepared by recombinant human TSH or by hormone withdrawal, neither at first nor at the second control. Radioablation was considered successful in 88.6% of patients prepared by recombinant human TSH, and 88.1% of those prepared by hormone withdrawal. No serious adverse events were related to recombinant TSH administration.
The study indicates that activity of 1850 MBq (50 mCi) seems to be optimal to achieve a successful ablation rate (~ 90%). Low I-131 activities are acceptable for lower risk patients because of satisfactory ablation rate (> 70%), lower expenses, and minimal radiation burden to patients as well as lower radiation exposure to clinical staff. The ablative use of high activities seems neither justified nor optimized. Also, study demonstrates comparable remnant ablation rates in patients prepared for radioiodine remnant ablation with 1850 MBq (50 mCi) by either administering rhTSH or withholding thyroid hormone. In both cases 1850 MBq (50 mCi) dose of radioiodine was sufficient for a satisfactory thyroid ablation rate
Diffuse sclerosing variant of thyroid carcinoma presenting as Hashimoto thyroiditis: a case report [Difuzno sklerozirajuÄi oblik papilarnog karcinoma Å”titnjaÄe nalik Hashimoto tireoiditisu: prikaz sluÄaja]
The aim of report is to present a case of a rare diffuse sclerosing variant of a papillary thyroid carcinoma. A 15-year old girl referred for ultrasound examination because of painless thyroid swelling lasting 10 days before. An ultrasound of the neck showed diffusely changed thyroid parenchyma, without nodes, looking as lymphocytic thyroiditis Hashimoto at first, but with snow-storm appearance, predominantly in the right lobe. Positive thyroid peroxidase antibodies (TPO-AT) also suggested Hashimoto thyroiditis. Repeated US-FNAB (fine needle-aspiration biopsy) of the right lobe revealed diffuse sclerosing variant of papillary thyroid carcinoma and patient underwent total thyreoidectomy. Patohistologic finding confirmed diffuse sclerosing variant of a papillary thyroid carcinoma in the both thyroid lobes and several metastatic lymph nodes. Two months later patient recived radioablative therapy with 3700 MBq (100 mCi) of 1-131 followed by levothyroxine replacement. At the moment, patient is without evidence of local or distant metastases and next regular control is scheduled in 6 months. In conclusion, a diffuse sclerosing variant is rare form of papillary thyroid carcinoma that echographically looks similar to Hashimoto thyroiditis and sometimes could be easily overlooked
Diffuse Sclerosing Variant of Thyroid Carcinoma Presenting as Hashimoto Thyroiditis: A Case Report
The aim of report is to present a case of a rare diffuse sclerosing variant of a papillary thyroid carcinoma. A 15- year old girl referred for ultrasound examination because of painless thyroid swelling lasting 10 days before. An ultrasound of the neck showed diffusely changed thyroid parenchyma, without nodes, looking as lymphocytic thyroiditis Hashimoto at first, but with Ā»snow-stormĀ« appearance, predominantly in the right lobe. Positive thyroid peroxidase antibodies
(TPO-AT) also suggested Hashimoto thyroiditis. Repeated US-FNAB (fine needle-aspiration biopsy) of the right lobe revealed diffuse sclerosing variant of papillary thyroid carcinoma and patient underwent total thyreoidectomy. Patohistologic finding confirmed diffuse sclerosing variant of a papillary thyroid carcinoma in the both thyroid lobes and several metastatic lymph nodes. Two months later patient recived radioablative therapy with 3700 MBq (100 mCi) of I-131 followed by levothyroxine replacement. At the moment, patient is without evidence of local or distant metastases and next regular control is scheduled in 6 months. In conclusion, a diffuse sclerosing variant is rare form of papillary thyroid carcinoma that echographically looks similar to Hashimoto thyroiditis and sometimes could be easily overlooked
Primjena inhibitora kinaza u lijeÄenju bolesnika s uznapredovalim rakom Å”titnjaÄe
Although most patients with thyroid cancer have a favorable clinical course, some
patients develop a more aggressive type of cancer and exhibit more rapid disease progression with
worse prognosis. Those patients usually exhibit mutations of proteins such as tyrosine kinase enzymes
that play a significant role in regulation of tumor proliferation and spreading. Development of targeted
therapies is based on the inhibition of mutated kinases which are involved in the MAPK signaling
pathway. The aim of this study was to present the initial results of clinical experience with kinase
inhibitors in patients with metastatic differentiated thyroid cancer (DT C), poorly differentiated thyroid
cancer (PDT C), and medullary thyroid cancer (MTC) who exhibited rapid disease progression.
A total of 17 adult patients (11 women, mean age 53.3 years) managed for progressive, metastatic
disease were included in the study. Twelve patients with DT C and PDT C were previously tested for
BRAF mutations, of whom nine that had tumor tissue negative for the BRAF V600E mutation received
sorafenib, while three patients with tumors harboring the BRAF V600E mutation were treated
with vemurafenib. Patients with MTC were treated with sunitinib, vandetanib, and sorafenib. Two
patients with tumors harboring the BRAF mutation treated with vemurafenib showed restoration of
radioiodine uptake. Most of patients showed significant improvement in disease status but of limited
duration until disease progression. Although there was an improvement in progression-free survival,
future research has to achieve a greater and longer-lasting response, probably by utilizing combined
targeted therapy.Iako veÄina bolesnika s karcinomom Å”titnjaÄe ima povoljan kliniÄki tijek, ipak neki bolesnici pokazuju agresivniji tijek
bolesti s razvojem uznapredovalih formi tumora i loŔijom prognozom. Razlog su vjerojatno mutacije proteina, uglavnom
enzima tirozin kinaza koji imaju znaÄajnu ulogu u proliferaciji i rastu tumora. Razvoj ciljanih terapija zasnovan je na inhibiranju
mutiranih kinaza BRAF, MEK, NRAS, c-KIT koje su ukljuÄene u signalni put MAPK. U radu su predstavljeni preliminarni
rezultati lijeÄenja inhibitorima kinaza u bolesnika s metastatskim diferenciranim karcinomom Å”titnjaÄe (DT C),
slabo diferenciranim karcinomom Å”titnjaÄe (PDT C) i medularnim karcinomom Å”titnjaÄe (MTC). U izvjeÅ”Äe je ukljuÄeno
ukupno 17 odraslih bolesnika (11 žena, prosjeÄna dob 53,3 godine) lijeÄenih zbog progresivne, metastatske bolesti. Dvanaest
bolesnika s DT C i PDT C prethodno je testirano na BRAF mutacije. Devet bolesnika kod kojih je tumorsko tkivo bilo negativno
na mutaciju BRAF V600E primali su sorafenib, dok su tri bolesnika s tumorima koji nose mutaciju BRAF V600E
lijeÄena vemurafenibom u cilju rediferencijacije tumora, a u dva bolesnika doÅ”lo je do ponovne akumulacije radiojoda na
scintigramu tijela. Bolesnici s MTC-om lijeÄeni su sunitinibom, vandetanibom i sorafenibom. U veÄine bolesnika doÅ”lo je do
pozitivnog terapijskog odgovora uz poboljÅ”anje stanja, ali ograniÄenog trajanja. BuduÄa istraživanja bi trebala osigurati bolji
i trajniji terapijski odgovor, vjerojatno primjenom kombinirane ciljane terapije
Dezmoidni tumor u ležiÅ”tu Å”titnjaÄe: prikaz bolesnika
SAŽETAK
Dezmoidni tumori su rijetke benigne tvorbe podrijetla vezivnog tkiva koje sporo rastu, ne metastaziraju, ali mogu invadirati okolna tkiva. Cilj izvjeÅ”Äa je prikaz bolesnice s dezmoidnim tumorom razvijenim u ležiÅ”tu lijevog režnja Å”titnjaÄe nakon prethodnoga operacijskog zahvata totalne tireoidektomije zbog multinodularne guÅ”e s ekstirpacijom adenoma paratireoidne žlijezde u istom aktu. Zbog promuklosti i osjeÄaja bolnosti u ležiÅ”tu Å”titnjaÄe dvije godine nakon inicijalnog zahvata kod bolesnice je uÄinjen kontrolni ultrazvuk vrata koji verificira slabo ograniÄen, nehomogen, pretežno izoehogen Ävor tvrde konzistencije u ležiÅ”tu lijevog režnja Å”titnjaÄe koji je po svojim ehografskim karakteristikama bio suspektan na malignu promjenu. Ciljana citoloÅ”ka punkcija opisuje rijetke vretenaste stanice, ali bez drugih elemenata za pobližu diferencijaciju. Stoga je ultrazvuÄni pregled dopunjen drugim slikovnim radioloÅ”kim metodama (kompjutorizirana tomografija i magnetska rezonancija) koje postavljaju sumnju na paragangliom ili adenom paratireoidne žlijezde, ali se nije mogla sa sigurnoÅ”Äu iskljuÄiti ni promjena druge etiologije. Zbog navedenog kod bolesnice je preporuÄena kirurÅ”ka ekscizija koja je bila zahtjevna zbog tvrdoÄe navedene tvorbe. PatohistoloÅ”ki nalaz je odgovarao ekstraabdominalnoj fibromatozi, odnosno dezmoidnom tumoru s moguÄom pojavom recidiva. Iako je dezmoidni tumor opÄenito benigna bolest, ponekad može biti lokalno invazivan s infiltracijom okolnih struktura oponaÅ”ajuÄi sliku malignog procesa uz otežanu potpunu kirurÅ”ku eksciziju koja je terapija izbora. Å toviÅ”e, unatoÄ potpunom uklanjanju Äest je recidiv bolesti pa bolesnike s dezmoidnim tumorom treba povremeno kontrolirati
Are kidney malformations an additional feature of MEN2B syndrome? ā Case report and literature review
Sindrom multiple endokrine neoplazije 2B (MEN2B) rijetka je autosomno dominatno nasljedna bolest uzrokovana mutacijama protoonkogena RET. Karakteriziran je pojavom medularnog karcinoma Å”titnjaÄe veÄ od rane, nerijetko dojenaÄke dobi, feokromocitoma koji je najÄeÅ”Äe obostran, sluzniÄkim neuromima te drugim ekstraendokrinim manifestacijama i specifiÄnim fenotipskim znaÄajkama koje mogu pomoÄi u prepoznavanju ovih bolesnika. Prikazujemo pacijenta sa sindromom MEN2B, dijabetesom melitusom tipa 1, inverznim položajem organa te priroÄenim malformacijama bubrega i mokraÄnog sustava. Pregledom literature uoÄeno je da se malformacije mokraÄnog sustava opisuju i u drugih bolesnika sa sindromom MEN2B. Prepoznata uloga gena RET u razvoju anomalija mokraÄnog sustava Äini moguÄu etioloÅ”ku poveznicu sa sindromom MEN2B. Predlažemo da se malformacije bubrega razmotre kao jedno od obilježja sindroma MEN2B. BuduÄi da se osobine bolesnika sa sindromom MEN2B postupno razvijaju s dobi, prepoznavanje priroÄene mane, uz prve znakove ostalih fenotipskih znaÄajki, moglo bi pomoÄi ranom postavljanju dijagnoze i lijeÄenju ovih bolesnika.Multiple endocrine neoplasia type 2B (MEN2B) is a rare familial syndrome caused by autosomal dominant mutations in the RET proto-oncogene. The disease is characterized by aggressive, early-onset medullary thyroid carcinoma, pheochromocytoma, most often bilateral, and mucosal neuromas together with other distinctive extra-endocrine manifestations and phenotypic features that can help in recognizing the patients and diagnosing the disease. We present the patient with MEN2B syndrome, type 1 diabetes mellitus, situs inversus and congenital kidney and urinary tract malformation. Reviewing the literature revealed other reports on urinary tract malformations in patients suffering from MEN2B. The recognized role of RET gene in kidney development and urinary tract malformations suggests a possible etiological link with MEN2B syndrome. We suggest that urinary tract malformations might be a feature of MEN2B syndrome. As most of the phenotype characteristics of the syndrome develop with age, recognizing congenital malformation might help in early diagnosing and treating the patients
Platelet serotonin concentration and monoamine oxidase activity in hypothyroid patients
BACKGROUND/AIM: The relationship between the hypothalamic-pituitary-thyroid (HPT) axis and the serotonergic (5-hydroxytryptamine, 5-HT) system is not clear. The aim of the study was to determine platelet biochemical markers (5-HT concentration and monoamine oxidase B, MAO-B, activity) in hypothyroid patients. ----- METHODS: The study included 25 medication-free female hypothyroid patients in postoperative follow-up after total thyroidectomy due to papillary thyroid carcinoma, who had not been treated with synthetic thyroxine (T(4)) for 4 weeks, and 44 age-matched euthyroid healthy women. The platelet 5-HT concentration, platelet MAO-B activity, total T(4) and thyroid-stimulating hormone (TSH) levels were determined using spectrofluorimetric methods, radioimmunoassay and fluoroimmunoassay, respectively. ----- RESULTS: Hypothyroid patients had significantly higher TSH, significantly lower T(4) levels and platelet 5-HT concentrations, and unchanged platelet MAO-B activity than healthy subjects. A positive correlation was found between the 5-HT concentration and platelet MAO-B activity, and between the platelet MAO-B activity and T(4) in control subjects. ----- CONCLUSIONS: Reduced platelet 5-HT concentrations in hypothyroid patients suggests a complex interaction between the 5-HT system and HPT axis activity, which could be related to the frequent occurrence of depressive symptoms in hypothyroid patients. The determination of platelet 5-HT concentrations should be considered a diagnostic tool for the evaluation of depressive symptoms in hypothyroid patients during the hormone withdrawal procedure
Efficacy of long-term ultrasonography in follow-up of patients with papillary thyroid carcinoma: a case of neck metastasis developed 19 years following primary treatment
The cases of relapse in papillary thyroid cancer patients who were initially considered low-risk and for many years were without signs of the disease are extremely rare, but exist. This is supported by the clinical case of a patient who underwent a total thyroidectomy due to papillary thyroid cancer and 19 years later metastasis with extracapsular spreading in a presumed thyroid place was revealed. Due to such cases, the importance of long-term ultrasound monitoring is emphasized
Awareness of EUGOGO guidelines and attitudes regarding smoking in Graves' orbithopathy in Croatia
Jesu li bubrežne malformacije jedno od obilježja sindroma MEN2B? ā prikaz bolesnika i pregled literature
Sindrom multiple endokrine neoplazije 2B (MEN2B) rijetka je autosomno dominatno nasljedna bolest uzrokovana mutacijama protoonkogena RET. Karakteriziran je pojavom medularnog karcinoma Å”titnjaÄe veÄ od rane, nerijetko dojenaÄke dobi, feokromocitoma koji je najÄeÅ”Äe obostran, sluzniÄkim neuromima te drugim ekstraendokrinim manifestacijama i specifiÄnim fenotipskim znaÄajkama koje mogu pomoÄi u prepoznavanju ovih bolesnika. Prikazujemo pacijenta sa sindromom MEN2B, dijabetesom melitusom tipa 1, inverznim položajem organa te priroÄenim malformacijama bubrega i mokraÄnog sustava. Pregledom literature uoÄeno je da se malformacije mokraÄnog sustava opisuju i u drugih bolesnika sa sindromom MEN2B. Prepoznata uloga gena RET u razvoju anomalija mokraÄnog sustava Äini moguÄu etioloÅ”ku poveznicu sa sindromom MEN2B. Predlažemo da se malformacije bubrega razmotre kao jedno od obilježja sindroma MEN2B. BuduÄi da se osobine bolesnika sa sindromom MEN2B postupno razvijaju s dobi, prepoznavanje priroÄene mane, uz prve znakove ostalih fenotipskih znaÄajki, moglo bi pomoÄi ranom postavljanju dijagnoze i lijeÄenju ovih bolesnika